Yolanda Cockerham
Psychiatric/Mental Health · Baton Rouge, LANPI 1003066606
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.6% of the total across 449 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,442, 3.5 times the $997 reported in 2021. Among psychiatric/mental health clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 449 payments — averaging $24.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Neurocrine Biosciences, Inc.$2K
- AbbVie$2K
- Johnson & Johnson$1K
- Axsome Therapeutics, Inc.$620
- Otsuka America Pharmaceutical, Inc.$605
- plus $3K from 15 others
What the payments were for
- Food & beverage$10,53597%
- Education$3683%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 71 | $1,938 |
| Neurocrine Biosciences, Inc. | 79 | $1,937 |
| AbbVie | 74 | $1,611 |
| Johnson & Johnson | 52 | $1,387 |
| Axsome Therapeutics, Inc. | 14 | $620 |
| Otsuka America Pharmaceutical, Inc. | 29 | $605 |
| Alkermes, Inc. | 17 | $515 |
| Lundbeck LLC | 37 | $418 |
| Teva Pharmaceuticals USA, Inc. | 10 | $363 |
| Corium, LLC | 5 | $287 |
| Vanda Pharmaceuticals Inc. | 8 | $245 |
| E.r. Squibb & Sons, L.L.C. | 14 | $242 |
| Indivior Inc. | 8 | $146 |
| Collegium Pharmaceutical, Inc. | 3 | $138 |
| Sunovion Pharmaceuticals Inc. | 10 | $136 |
| Supernus Pharmaceuticals, Inc. | 6 | $118 |
| Ironshore Pharmaceuticals Inc. | 5 | $80 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $45 |
| Adlon Therapeutics L.p. | 3 | $43 |
| Tris Pharma Inc | 1 | $16 |
| Lilly USA, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$721
- VRAYLAR$463
- Auvelity$358
- INGREZZA$244
- SPRAVATO$232
- INVEGA SUSTENNA$230
- INVEGA TRINZA$130
- Azstarys$125
- ABILIFY MAINTENA$123
- ABILIFY ASIMTUFII$123
- UZEDY$122
- Fanapt$117
- JORNAY PM$105
- COBENFY$100
How this compares
$10,903 in reported general payments places this provider in the 95th percentile of 615 psychiatric/mental health providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 20 | $57,884 |
| VraylarCariprazine Hcl | 37 | $56,035 |
| Invega SustennaPaliperidone Palmitate | 12 | $28,480 |
| CaplytaLumateperone Tosylate | 12 | $20,647 |
| TrintellixVortioxetine Hydrobromide | 12 | $5,657 |
| Oxcarbazepine | 54 | $2,845 |
| Aripiprazole | 54 | $2,142 |
| Trazodone Hcl | 74 | $1,802 |
| Lurasidone Hcl | 16 | $1,790 |
| Olanzapine OdtOlanzapine | 28 | $1,365 |
| Clozapine | 22 | $1,238 |
| Hydroxyzine Hcl | 51 | $1,129 |
| Risperidone | 76 | $995 |
| Doxepin Hcl | 33 | $858 |
| Ziprasidone Hcl | 17 | $801 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $605 | $57,88420 claims |
| AbbVieVraylar | $1,611 | $56,03537 claims |
| Johnson & JohnsonInvega Sustenna | $1,387 | $28,48012 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,938 | $20,64712 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $45 | $5,65712 claims |
| Lilly USA, LLCOlanzapine | $11 | $44760 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 615 psychiatric/mental health providers in Louisiana.
Other psychiatric/mental health in Baton Rouge
- Amy LacoutureBaton Rouge$663K
- Drew DykesBaton Rouge$11K
- Tiffany JordanBaton Rouge$10K
- Elizabeth CasselberryBaton Rouge$9K
- Amanda EymardHouma$617K
- Amber LittlefieldBroussard$225K
- Timothy PellegrinHouma$210K
- Melissa GuilbeauLafayette$122K
- Kimberly ForcinelShreveport$92K
- Sattaria DilksLake Charles$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.